Advertisement
Screener

AMNEAL PHARMACEUTICALS, INC. (AMRX) Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders

2.8 / 5 stars · 68/120 Roast Me

AMNEAL PHARMACEUTICALS, INC. Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders

AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders of $56.70 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-27.

Financial Statements › Shareholders' Equity

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders · last filed 2026-02-27

  • AMNEAL PHARMACEUTICALS, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for the quarter ending 2023-12-31 was -$2.00M, a 353.16% decline year-over-year.
  • AMNEAL PHARMACEUTICALS, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for the quarter ending 2023-09-30 was $10.60M, a 327.42% increase year-over-year.
  • AMNEAL PHARMACEUTICALS, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for the quarter ending 2023-06-30 was $21.20M, a 633.56% increase year-over-year.
  • AMNEAL PHARMACEUTICALS, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for the quarter ending 2023-03-31 was $26.80M, a 503.60% increase year-over-year.
  • AMNEAL PHARMACEUTICALS, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for fiscal 2023 was $56.70M, a 434.91% increase from fiscal 2022.
  • AMNEAL PHARMACEUTICALS, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for fiscal 2022 was $10.60M, a 80.19% decline from fiscal 2021.
  • AMNEAL PHARMACEUTICALS, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for fiscal 2021 was $53.50M, a 1810.71% increase from fiscal 2020.
  • AMNEAL PHARMACEUTICALS, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for fiscal 2020 was $2.80M, a 2700.00% increase from fiscal 2019.
Period endNoncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 3 monthNoncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 3 month as first filedNoncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 5 monthNoncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 6 monthNoncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 6 month as first filedNoncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 9 monthNoncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 9 month as first filedNoncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 12 monthNoncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 12 month as first filed
2023-12-31-$2.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$8.60M
derived: sum of 2 quarters · filed 2026-02-27
$29.80M
derived: sum of 3 quarters · filed 2026-02-27
$56.70M
10-K · filed 2026-02-27
2023-09-30$10.60M
10-Q · filed 2024-11-12
$10.64M
10-Q · filed 2023-11-09
$31.80M
derived: sum of 2 quarters · filed 2024-11-12
$58.70M
10-Q · filed 2024-11-12
$58.65M
10-Q · filed 2023-11-09
$59.39M
derived: sum of 4 quarters · filed 2025-02-28
2023-06-30$21.20M
10-Q · filed 2024-08-09
$48.00M
10-Q · filed 2024-08-09
$48.01M
10-Q · filed 2023-08-08
$48.79M
derived: sum of 3 quarters · filed 2025-02-28
$51.27M
derived: sum of 4 quarters · filed 2025-02-28
2023-03-31$26.80M
10-Q · filed 2024-05-08
$26.81M
10-Q · filed 2023-05-09
$27.59M
derived: sum of 2 quarters · filed 2025-02-28
$30.07M
derived: sum of 3 quarters · filed 2025-02-28
$32.96M
derived: sum of 4 quarters · filed 2025-02-28
2022-12-31$790.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
$3.27M
derived: sum of 2 quarters · filed 2025-02-28
$6.16M
derived: sum of 3 quarters · filed 2025-02-28
$10.60M
10-K · filed 2025-02-28
2022-09-30$2.48M
10-Q · filed 2023-11-09
$2.50M
10-Q · filed 2022-11-07
$5.37M
derived: sum of 2 quarters · filed 2023-11-09
$9.81M
10-Q · filed 2023-11-09
$9.80M
10-Q · filed 2022-11-07
$28.81M
derived: sum of 4 quarters · filed 2024-03-14
2022-06-30$2.89M
10-Q · filed 2023-08-08
$2.90M
10-Q · filed 2022-08-08
$7.33M
10-Q · filed 2023-08-08
$7.30M
10-Q · filed 2022-08-08
$26.33M
derived: sum of 3 quarters · filed 2024-03-14
$34.93M
derived: sum of 4 quarters · filed 2024-03-14
2022-03-31$4.44M
10-Q · filed 2023-05-09
$4.40M
10-Q · filed 2022-05-06
$23.44M
derived: sum of 2 quarters · filed 2024-03-14
$32.04M
derived: sum of 3 quarters · filed 2024-03-14
$48.64M
derived: sum of 4 quarters · filed 2024-03-14
2021-12-31$19.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
$27.60M
derived: sum of 2 quarters · filed 2024-03-14
$44.20M
derived: sum of 3 quarters · filed 2024-03-14
$53.50M
10-K · filed 2024-03-14
$53.00M
10-K · filed 2022-03-01
2021-09-30$8.60M
10-Q · filed 2022-11-07
$9.00M
10-Q · filed 2021-11-08
$25.20M
derived: sum of 2 quarters · filed 2022-11-07
$34.50M
10-Q · filed 2022-11-07
$34.00M
10-Q · filed 2021-11-08
$36.20M
derived: sum of 4 quarters · filed 2023-03-03
2021-06-30$16.60M
10-Q · filed 2022-08-08
$17.00M
10-Q · filed 2021-08-09
$25.90M
10-Q · filed 2022-08-08
$26.00M
10-Q · filed 2021-08-09
$27.60M
derived: sum of 3 quarters · filed 2023-03-03
$27.60M
derived: sum of 4 quarters · filed 2023-03-03
2021-03-31$9.20M
10-Q · filed 2022-05-06
$9.00M
10-Q · filed 2021-05-07
$11.00M
derived: sum of 2 quarters · filed 2023-03-03
$11.00M
derived: sum of 3 quarters · filed 2023-03-03
$12.00M
derived: sum of 4 quarters · filed 2023-03-03
2020-12-31$1.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03
$1.80M
derived: sum of 2 quarters · filed 2023-03-03
$2.80M
derived: sum of 3 quarters · filed 2023-03-03
$2.80M
10-K · filed 2023-03-03
$3.00M
10-K · filed 2021-03-01
2020-09-30$0.00
10-Q · filed 2021-11-08
$1.00M
derived: sum of 2 quarters · filed 2021-11-08
$1.00M
10-Q · filed 2021-11-08
$1.00M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$1.00M
10-Q · filed 2021-08-09
$1.00M
10-Q · filed 2021-08-09
$1.00M
derived: sum of 3 quarters · filed 2022-03-01
$1.00M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$0.00
10-Q · filed 2021-05-07
$0.00
derived: sum of 2 quarters · filed 2022-03-01
$0.00
derived: sum of 3 quarters · filed 2022-03-01
$0.00
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$0.00
derived: sum of 2 quarters · filed 2022-03-01
$0.00
derived: sum of 3 quarters · filed 2022-03-01
$100.00K
10-K · filed 2022-03-01
$0.00
10-K · filed 2020-03-02
2019-09-30$0.00
10-Q · filed 2020-11-06
$0.00
derived: sum of 2 quarters · filed 2020-11-06
$100.00K
10-Q · filed 2020-11-06
$13.50M
derived: sum of 4 quarters · filed 2020-11-06
2019-06-30$0.00
10-Q · filed 2020-08-06
$0.00
10-Q · filed 2020-08-06
$13.50M
derived: sum of 3 quarters · filed 2020-08-06
$49.00M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31$0.00
10-Q · filed 2020-05-11
$13.50M
derived: sum of 2 quarters · filed 2020-05-11
$49.00M
derived: sum of 3 quarters · filed 2020-05-11
2018-12-31$13.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$49.00M
derived: sum of 2 quarters · filed 2020-03-02
$49.00M
10-K · filed 2020-03-02
2018-09-30$35.50M
10-Q · filed 2018-11-07
$35.54M
10-Q · filed 2018-11-07
$35.50M
10-Q · filed 2018-11-07
2017-12-31$865.00K
10-K · filed 2019-03-01
2016-12-31$973.00K
10-K · filed 2019-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Liquidia Corp (LQDA)United States$6.347B51.23
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
Alkermes plc. (ALKS)$6.844B132.74
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07